The AGENT drug coated balloon (DCB) continued to reduce target lesion failure (TLF) rates for in-stent restenosis (ISR) patients versus uncoated balloons over an extended 2-year follow-up period in the AGENT IDE trial, investigator Jeffrey Moses, MD, reported for the first time on Saturday at Cardiovascular Research Technologies (CRT) 2025.